
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current 0IJO market cap is 5.98B. The company's latest EPS is USD 1.8253 and P/E is 20.63.
Year End January 02 2025 | 2021 | 2021 | 2022 | 2023 | 2025 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 987.54M | 1.43B | 1.61B | 1.83B | 2.17B |
Operating Income | 110.06M | 286.67M | 201.48M | 170.89M | 656.29M |
Net Income | 111.78M | 231.06M | 182.28M | 207.77M | 521.27M |
Year End January 02 2025 | 2021 | 2021 | 2022 | 2023 | 2025 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 2.14B | 2.62B | 3.07B | 2.94B | 2.95B |
Total Liabilities | 258.22M | 405.62M | 583.06M | 678.45M | 703.49M |
Total Equity | 1.88B | 2.21B | 2.49B | 2.26B | 2.24B |
Year End January 02 2025 | 2021 | 2021 | 2022 | 2023 | 2025 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | 208.98M | 400.8M | 362.61M | 333.32M | 699.97M |
Investing | -131.22M | -42.88M | -524.41M | -26.96M | -116.78M |
Financing | -25.13M | -14.8M | 586k | -546.05M | -628.81M |
Market Cap | 5.98B |
Price to Earnings Ratio | 20.63 |
Price to Sales Ratio | 4.96 |
Price to Cash Ratio | 49.46 |
Price to Book Ratio | 4.79 |
Dividend Yield | - |
Shares Outstanding | 285.58M |
Average Volume (1 week) | 4.56k |
Average Volume (1 Month) | 2.5k |
52 Week Change | 0.00% |
52 Week High | 20.93 |
52 Week Low | 20.93 |
Spread (Intraday) | 0 (0%) |
Company Name | Exelixis Inc |
Address |
251 little falls drive wilmington, delaware 19808 |
Website | https://www.exelixis.com |
Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions